[Therapy of reflux esophagitis with antacids].
At present it has not been sufficiently established by controlled trials that antacids are more efficacious in the treatment of reflux symptoms and reflux esophagitis than placebo. Furthermore, Gaviscon does not seem to offer advantages in comparison to traditional antacids. It is suggested that the value of antacids in the treatment of reflux esophagitis should be further evaluated in controlled studies using higher antacid dosages for more extended periods of time, at least 8 to 12 weeks.
D000863:Antacids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D006801:Humans
D000863:Antacids
Therapie der Refluxösophagitis mit Antazida.